School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Precision Medicine Laboratory, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Pharm Biol. 2024 Dec;62(1):529-543. doi: 10.1080/13880209.2024.2369292. Epub 2024 Jun 26.
Diabetic retinopathy (DR) is one of the leading causes of vision impairment and blindness among diabetic patients globally. Despite advancements in conventional treatments, the quest for more holistic approaches and fewer side effects persists. Traditional Chinese medicine (TCM) has been used for centuries in managing various diseases, including diabetes and its complications.
This review evaluated the efficacy and underlying mechanisms of TCM in the management of DR, providing information on its potential integration with conventional treatment methods.
A comprehensive literature review was conducted using PubMed, Web of Science, and the China National Knowledge Infrastructure (CNKI) with the search terms 'traditional Chinese medicine', 'diabetic retinopathy', 'clinical efficacies' and their combinations. Studies published before 2023 without language restriction were included, focusing on clinical trials and observational studies that assessed the effectiveness of TCM in DR treatment.
The review synthesized evidence of empirical traditional Chinese formulas, traditional Chinese patent medicines, and isolated phytochemicals on DR treatment. The key mechanisms identified included the reduction of oxidative stress, inflammation, and neovascularization, as well as the improvement in neurovascular functionality and integrity of the retinal blood barrier.
TCM shows promising potential to manage DR. More large-scale, randomized controlled trials are recommended to validate these findings and facilitate the integration of TCM into mainstream DR treatment protocols.
糖尿病视网膜病变(DR)是全球糖尿病患者视力损害和失明的主要原因之一。尽管常规治疗方法有所进步,但人们仍然在寻求更全面的方法和更少的副作用。传统中药(TCM)在治疗各种疾病方面已有数百年的历史,包括糖尿病及其并发症。
本综述评估了 TCM 在 DR 管理中的疗效和潜在机制,提供了关于其与常规治疗方法相结合的潜在信息。
使用 PubMed、Web of Science 和中国国家知识基础设施(CNKI),使用“传统中药”、“糖尿病视网膜病变”、“临床疗效”及其组合等术语进行了全面的文献综述。纳入了 2023 年前发表的、无语言限制的研究,重点是评估 TCM 在 DR 治疗中的有效性的临床试验和观察性研究。
综述综合了中药方剂、中药成药和中药单体在 DR 治疗方面的经验证据。确定的关键机制包括减轻氧化应激、炎症和新生血管形成,以及改善神经血管功能和视网膜血屏障的完整性。
TCM 显示出治疗 DR 的潜力。建议进行更多的大规模、随机对照试验,以验证这些发现,并促进 TCM 纳入主流 DR 治疗方案。